Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 4;16(3):399.
doi: 10.3390/v16030399.

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review

Carolyn Chu  1 , Kaiming Tao  2 , Vinie Kouamou  3 , Ava Avalos  4 , Jake Scott  2 , Philip M Grant  2 , Soo-Yon Rhee  2 , Suzanne M McCluskey  5 , Michael R Jordan  6   7 , Rebecca L Morgan  8 , Robert W Shafer  2
Affiliations

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review

Carolyn Chu et al. Viruses. .

Abstract

Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART.

Methods: We performed a PubMed search using the term "Dolutegravir", last updated 18 December 2023, to estimate the prevalence of VF with emergent INSTI DRMs in people living with HIV (PLWH) without previous VF on an INSTI who received DTG-containing ART.

Results: Of 2131 retrieved records, 43 clinical trials, 39 cohorts, and 6 cross-sectional studies provided data across 6 clinical scenarios based on ART history, virological status, and co-administered ARVs: (1) ART-naïve PLWH receiving DTG plus two NRTIs; (2) ART-naïve PLWH receiving DTG plus lamivudine; (3) ART-experienced PLWH with VF on a previous regimen receiving DTG plus two NRTIs; (4) ART-experienced PLWH with virological suppression receiving DTG plus two NRTIs; (5) ART-experienced PLWH with virological suppression receiving DTG and a second ARV; and (6) ART-experienced PLWH with virological suppression receiving DTG monotherapy. The median proportion of PLWH in clinical trials with emergent INSTI DRMs was 1.5% for scenario 3 and 3.4% for scenario 6. In the remaining four trial scenarios, VF prevalence with emergent INSTI DRMs was ≤0.1%. Data from cohort studies minimally influenced prevalence estimates from clinical trials, whereas cross-sectional studies yielded prevalence data lacking denominator details.

Conclusions: In clinical trials, the prevalence of VF with emergent INSTI DRMs in PLWH receiving DTG-containing regimens has been low. Novel approaches are required to assess VF prevalence with emergent INSTI DRMs in PLWH receiving DTG in real-world settings.

Keywords: HIV; epidemiology; systematic review; treatment.

PubMed Disclaimer

Conflict of interest statement

Robert W. Shafer has received honoraria for participation in advisory boards from Gilead Sciences and GlaxoSmithKline and speaking honoraria from Gilead Sciences and ViiV Healthcare.

Figures

Figure 1
Figure 1
Flow chart summarizing the review process. Of 2131 publications identified in the PubMed search, 345 were read in their entirety following an initial review of titles and abstracts. Exclusions for clinical trials and cross-sectional studies were usually based on a single exclusion criterion. Exclusions for cohort studies were usually based on more than one exclusion criterion. Two publications contained descriptions of two cohorts. Abbreviations: PK—pharmacokinetic study; PLWH—people living with HIV; GRT—genotypic resistance testing; VF—virological failure; 1st-gen INSTI—previous VF on a 1st-generation integrase strand transfer inhibitor (raltegravir or elvitegravir). Heterogeneous/Missing data—indicates that the study described different subsets of individuals with different ART histories, levels of virus suppression, and DTG-containing regimens but that the virological and/or GRT outcomes were not provided for the different subsets.
See this image and copyright information in PMC

References

    1. World Health Organization Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. [(accessed on 17 August 2022)]. Available online: https://www.who.int/publications-detail-redirect/9789240031593. - PubMed
    1. Clinton Health Access Initiative . The State of HIV Treatment, Testing, and Prevention in Low- and Middle-Income Countries. Clinton Health Access Initiative; Boston, MA, USA: 2023. HIV Market Report 2023.
    1. Tao K., Rhee S.-Y., Chu C., Avalos A., Ahluwalia A.K., Gupta R.K., Jordan M.R., Shafer R.W. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review. Viruses. 2023;15:1932. doi: 10.3390/v15091932. - DOI - PMC - PubMed
    1. Tzou P.L., Rhee S.-Y., Descamps D., Clutter D.S., Hare B., Mor O., Grude M., Parkin N., Jordan M.R., Bertagnolio S., et al. Integrase Strand Transfer Inhibitor (INSTI)-Resistance Mutations for the Surveillance of Transmitted HIV-1 Drug Resistance. J. Antimicrob. Chemother. 2020;75:170–182. doi: 10.1093/jac/dkz417. - DOI - PMC - PubMed
    1. Tricco A.C., Lillie E., Zarin W., O’Brien K.K., Colquhoun H., Levac D., Moher D., Peters M.D.J., Horsley T., Weeks L., et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann. Intern. Med. 2018;169:467–473. doi: 10.7326/M18-0850. - DOI - PubMed

Publication types